271 related articles for article (PubMed ID: 35401506)
1. GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD
Glienke W; Dragon AC; Zimmermann K; Martyniszyn-Eiben A; Mertens M; Abken H; Rossig C; Altvater B; Aleksandrova K; Arseniev L; Kloth C; Stamopoulou A; Moritz T; Lode HN; Siebert N; Blasczyk R; Goudeva L; Schambach A; Köhl U; Eiz-Vesper B; Esser R
Front Immunol; 2022; 13():839783. PubMed ID: 35401506
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
3. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
[TBL] [Abstract][Full Text] [Related]
4. Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-G
Zimmermann K; Kuehle J; Dragon AC; Galla M; Kloth C; Rudek LS; Sandalcioglu IE; Neyazi B; Moritz T; Meyer J; Rossig C; Altvater B; Eiz-Vesper B; Morgan MA; Abken H; Schambach A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32041222
[TBL] [Abstract][Full Text] [Related]
5. CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation.
Dragon AC; Zimmermann K; Nerreter T; Sandfort D; Lahrberg J; Klöß S; Kloth C; Mangare C; Bonifacius A; Tischer-Zimmermann S; Blasczyk R; Maecker-Kolhoff B; Uchanska-Ziegler B; Abken H; Schambach A; Hudecek M; Eiz-Vesper B
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33127653
[TBL] [Abstract][Full Text] [Related]
6. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
Front Immunol; 2019; 10():2361. PubMed ID: 31649672
[TBL] [Abstract][Full Text] [Related]
7. Generation of an NFκB-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy.
Rudek LS; Zimmermann K; Galla M; Meyer J; Kuehle J; Stamopoulou A; Brand D; Sandalcioglu IE; Neyazi B; Moritz T; Rossig C; Altvater B; Falk CS; Abken H; Morgan MA; Schambach A
Front Immunol; 2021; 12():751138. PubMed ID: 34804035
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
Fischer-Riepe L; Kailayangiri S; Zimmermann K; Pfeifer R; Aigner M; Altvater B; Kretschmann S; Völkl S; Hartley J; Dreger C; Petry K; Bosio A; von Döllen A; Hartmann W; Lode H; Görlich D; Mackensen A; Jungblut M; Schambach A; Abken H; Rossig C
Clin Cancer Res; 2024 Apr; ():OF1-OF14. PubMed ID: 38593230
[TBL] [Abstract][Full Text] [Related]
9. Choosing T-cell sources determines CAR-T cell activity in neuroblastoma.
García-García L; G Sánchez E; Ivanova M; Pastora K; Alcántara-Sánchez C; García-Martínez J; Martín-Antonio B; Ramírez M; González-Murillo Á
Front Immunol; 2024; 15():1375833. PubMed ID: 38601159
[TBL] [Abstract][Full Text] [Related]
10. Co-Expression of an IL-15 Superagonist Facilitates Self-Enrichment of GD
Bodden M; Häcker A; Röder J; Kiefer A; Zhang C; Bhatti A; Pfeifer Serrahima J; Ullrich E; Kühnel I; Wels WS
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686586
[TBL] [Abstract][Full Text] [Related]
11. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
12. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration.
Malakhova E; Pershin D; Kulakovskaya E; Vedmedskaia V; Fadeeva M; Lodoeva O; Sozonova T; Muzalevskii Y; Kazachenok A; Belchikov V; Shelikhova L; Molostova O; Volkov D; Maschan M
Cytotherapy; 2024 Jun; 26(6):567-578. PubMed ID: 38493403
[TBL] [Abstract][Full Text] [Related]
13. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
Andersch L; Radke J; Klaus A; Schwiebert S; Winkler A; Schumann E; Grunewald L; Zirngibl F; Flemmig C; Jensen MC; Rossig C; Joussen A; Henssen A; Eggert A; Schulte JH; Künkele A
BMC Cancer; 2019 Sep; 19(1):895. PubMed ID: 31500597
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation.
Jiang G; Neuber B; Hückelhoven-Krauss A; Höpken UE; Ding Y; Sedloev D; Wang L; Reichman A; Eberhardt F; Wermke M; Rehm A; Müller-Tidow C; Schmitt A; Schmitt M
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338672
[TBL] [Abstract][Full Text] [Related]
15. CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans.
Nicod C; da Rocha MN; Warda W; Roussel X; Haderbache R; Seffar E; Trad R; Bouquet L; Goncalves M; Bosdure L; Laude MC; Guiot M; Ferrand C; Deschamps M
Curr Res Transl Med; 2023; 71(2):103385. PubMed ID: 36773434
[TBL] [Abstract][Full Text] [Related]
16. Induction of a central memory and stem cell memory phenotype in functionally active CD4
Blaeschke F; Stenger D; Kaeuferle T; Willier S; Lotfi R; Kaiser AD; Assenmacher M; Döring M; Feucht J; Feuchtinger T
Cancer Immunol Immunother; 2018 Jul; 67(7):1053-1066. PubMed ID: 29605883
[TBL] [Abstract][Full Text] [Related]
17. Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy® Platform.
Aleksandrova K; Leise J; Priesner C; Melk A; Kubaink F; Abken H; Hombach A; Aktas M; Essl M; Bürger I; Kaiser A; Rauser G; Jurk M; Goudeva L; Glienke W; Arseniev L; Esser R; Köhl U
Transfus Med Hemother; 2019 Feb; 46(1):47-54. PubMed ID: 31244581
[TBL] [Abstract][Full Text] [Related]
18. CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors.
Dragon AC; Beermann LM; Umland M; Bonifacius A; Malinconico C; Ruhl L; Kehler P; Gellert J; Weiß L; Mayer-Hain S; Zimmermann K; Riese S; Thol F; Beutel G; Maecker-Kolhoff B; Yamamoto F; Blasczyk R; Schambach A; Hust M; Hudecek M; Eiz-Vesper B
Front Immunol; 2023; 14():1219165. PubMed ID: 37915564
[TBL] [Abstract][Full Text] [Related]
19. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.
Sun J; Huye LE; Lapteva N; Mamonkin M; Hiregange M; Ballard B; Dakhova O; Raghavan D; Durett AG; Perna SK; Omer B; Rollins LA; Leen AM; Vera JF; Dotti G; Gee AP; Brenner MK; Myers DG; Rooney CM
J Immunother Cancer; 2015; 3():5. PubMed ID: 25734008
[TBL] [Abstract][Full Text] [Related]
20. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.
Gargett T; Ebert LM; Truong NTH; Kollis PM; Sedivakova K; Yu W; Yeo ECF; Wittwer NL; Gliddon BL; Tea MN; Ormsby R; Poonnoose S; Nowicki J; Vittorio O; Ziegler DS; Pitson SM; Brown MP
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]